INCB050465 (Parsaclisib), Emerging Drug Insight and Market Forecast - 2032

“INCB050465 (Parsaclisib), Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about INCB050465 (Parsaclisib) for Cold Agglutinin Disease in the 7MM. A detailed picture of the INCB050465 (Parsaclisib) for Cold Agglutinin Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the INCB050465 (Parsaclisib) for Cold Agglutinin Disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INCB050465 (Parsaclisib) market forecast, analysis for Cold Agglutinin Disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cold Agglutinin Disease.

Drug Summary

Parsaclisib is a potent and selective next-generation inhibitor of the delta isoform of the phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity that differs in structure from first generation PI3K inhibitors and has shown encouraging anti-B-cell tumor activity and reduced hepatotoxicity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival. Parsaclisib directly blocks PI3K signaling-mediated cell proliferation in B-cell lines in vitro and in vivo, and indirectly controls tumor growth by lessening immunosuppression through regulatory T-cell inhibition in a syngeneic lymphoma model.

Currently, the drug is in the Phase II (NCT03538041) clinical stage in patients with autoimmune hemolytic anemia. The trial is also ongoing in the EU Clinical trials register (2017-003652-22) for Autoimmune Hemolytic Anemia (AIHA) and also includes patients with cold AIHA.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the INCB050465 (Parsaclisib) description, mechanism of action, dosage and administration, research and development activities in Cold Agglutinin Disease.
• Elaborated details on INCB050465 (Parsaclisib) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the INCB050465 (Parsaclisib) research and development activity in Cold Agglutinin Disease details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around INCB050465 (Parsaclisib).
• The report contains forecasted sales of INCB050465 (Parsaclisib) for Cold Agglutinin Disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Cold Agglutinin Disease.
• The report also features the SWOT analysis with analyst views for INCB050465 (Parsaclisib) in Cold Agglutinin Disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INCB050465 (Parsaclisib) Analytical Perspective

In-depth INCB050465 (Parsaclisib) Market Assessment

This report provides a detailed market assessment of INCB050465 (Parsaclisib) in Cold Agglutinin Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

INCB050465 (Parsaclisib) Clinical Assessment

The report provides the clinical trials information of INCB050465 (Parsaclisib) in Cold Agglutinin Disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Cold Agglutinin Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INCB050465 (Parsaclisib) dominance.
• Other emerging products for Cold Agglutinin Disease are expected to give tough market competition to INCB050465 (Parsaclisib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INCB050465 (Parsaclisib) in Cold Agglutinin Disease.
• Our in-depth analysis of the forecasted sales data of INCB050465 (Parsaclisib) from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INCB050465 (Parsaclisib) in Cold Agglutinin Disease.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of INCB050465 (Parsaclisib)?
• What is the clinical trial status of the study related to INCB050465 (Parsaclisib) in Cold Agglutinin Disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INCB050465 (Parsaclisib) development?
• What are the key designations that have been granted to INCB050465 (Parsaclisib) for Cold Agglutinin Disease?
• What is the forecasted market scenario of INCB050465 (Parsaclisib) for Cold Agglutinin Disease?
• What are the forecasted sales of INCB050465 (Parsaclisib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Cold Agglutinin Disease and how are they giving competition to INCB050465 (Parsaclisib) for Cold Agglutinin Disease?
• Which are the late-stage emerging therapies under development for the treatment of Cold Agglutinin Disease?